Is This Beaten-Down Cathie Wood Artificial Intelligence (AI) Stock a Buy?

Recursion Pharmaceuticals (NASDAQ: RXRX) is not the most famous artificial intelligence (AI) stock on the market, but the biotech (or techbio) company has attracted the attention of some big names. Recursion has partnered with the AI juggernaut Nvidia to build a powerful supercomputer, for example.

It is also attracting interest from some prominent Wall Street figures, including Cathie Wood, the CEO of Ark Invest. The investment firm owns about $164 million worth of the stock, as of this writing. Yet, Recursion has not been performing well -- shares are down by 19% this year.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »

Should investors take this opportunity to buy the stock on the dip?

Image source: Getty Images.

Recursion's paradigm-shifting approach

People in the tech world are familiar with Moore's law, which predicts an exponential increase in computing power at a lower cost. Fewer people are familiar with Eroom's law (Moore's backward), the observation that the business of developing novel medicines has become more expensive even as technology has improved. Drugmakers spend considerable time and money to get their products to market. Most new compounds never go that far, and many that do hardly make enough money to justify the investment that went into them.

Recursion is looking to solve that problem. The company has developed an AI-powered operating system (OS) that features a library of human genes. This OS is constantly testing clinical compounds against this library. The most promising ones are chosen to be tested in the clinic. The potential benefits here could be faster discovery, faster development, lower costs, longer time spent under patent exclusivity on the market, higher sales, higher profits, and higher margins.

In other words, if Recursion Pharmaceuticals is successful, it could transform the pharmaceutical industry. Besides developing its own medicines, Recursion would also license out its AI-powered OS to other companies. That business might look even more attractive. It is far less cost-intensive than developing medicines (even if that becomes easier thanks to Recursion, it will still require tens of millions of dollars to undergo clinical trials), while also returning much higher margins.

That's why some investors like Wood are interested in the stock. The company's upside potential is massive. And it got an even rosier outlook earlier this year when the U.S. Food and Drug Administration announced that it would be slowly phasing out animal testing in pre-clinical trials in favor of other methods, including AI-based models.

It might look as though Recursion'a approach is the future. So why isn't the stock soaring, then?

High risk, high reward

Recursion Pharmaceuticals has yet to show the kind of evidence that would convince most investors that its approach works. The company doesn't have a single product on the market. Worse, it doesn't even have a single product in phase 3 studies. In fact, the biotech recently abandoned the development of several compounds. While management said this was to focus on other, more promising candidates, that move still doesn't bode well for a company that claims to be able to transform the way medicines are developed.

It's also worth noting that other companies have recognized the potential for AI to transform the industry. Novo Nordisk, through its parent company, helped build an AI supercomputer in Denmark, where it is based, because of the technology's potential across healthcare, including in drug development. Recursion hopes that its AI-based OS will become more fine-tuned thanks to future successes and even failures. In other words, data from clinical trials is important, and that's an advantage that more experienced companies, such as Novo Nordisk, will have over smaller, younger biotechs.

So what should investors do?

Recursion Pharmaceuticals carries above-average risk because of its status as a clinical-stage biotech company, but it could also deliver life-changing returns if it achieves its goals. Risk-tolerant investors might consider initiating a small position in the stock, just like Wood did. The company makes up 1.65% of Ark Invest's combined portfolio, as of this writing. Those comfortable with volatility can start somewhere there (or lower). Risk-averse investors, though, should look elsewhere.

Should you invest $1,000 in Recursion Pharmaceuticals right now?

Before you buy stock in Recursion Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Recursion Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $653,702!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $870,207!*

Now, it’s worth noting Stock Advisor’s total average return is 988% — a market-crushing outperformance compared to 172% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of June 9, 2025

Prosper Junior Bakiny has positions in Novo Nordisk, Nvidia, and Recursion Pharmaceuticals. The Motley Fool has positions in and recommends Nvidia. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.